Bridging the gap between innovation and capital
Chiesi Global Rare Diseases
Focus on Rare Diseases
Program
As a family-owned and family-run biopharmaceutical company, Chiesi Global Rare Diseases is driven by a simple but powerful mission: to make a meaningful difference in the lives of every person and family affected by rare diseases.
Event
LaunchBio, Browne Consulting, and Silicon Valley Bank, a division of First Citizens Bank, with support by Fondation Ipsen, are pleased to announce their next Investor Connect virtual event with Chiesi Global Rare Diseases.
Chiesi Global Rare Diseases is actively exploring opportunities to expand into innovative therapeutic modalities within its core areas of expertise, as well as in adjacent fields, including in vivo gene editing, in vivo gene therapies, and delivery vectors with organ specificity.
They are looking to partner with companies developing innovative therapeutic assets and platforms that can provide significant benefits to patients, healthcare providers, and payers in our core therapeutic areas. Its portfolio has been built through company acquisition or in-licensing assets. In the earlier stage, they are open to other types of collaboration.
Applications will be selected based on meeting the following criteria:
Geography
US, Europe, and Emerging Countries.
Modalities of Interest
- Biologics
- CRISPR-based therapies
- Gene therapies
- Protein-based therapies
- RNA-based therapeutics
- Small molecule
- Non-viral extrahepatic delivery vectors
Therapeutic Areas
- Hematology
- Immunonology
- Dermatology
- Ophthalmology
- Pulmonology
- Endometabolic
- Inborn Errors of Metabolism
(Chiesi does not invest in Oncology)
Stage
Depends on the partnership.
Qualifying start-ups can apply here today.
Applications are accepted on a rolling basis. Learn more about LaunchBio’s Investor Connect series, in partnership with Browne Consulting and Silicon Valley Bank, a division of First Citizens Bank.